274 related articles for article (PubMed ID: 32440108)
1. Association Between Adherence to Maintenance Medication in Patients with COPD and Acute Exacerbation Occurrence and Cost in China: A Retrospective Cohort Database Study.
Chen R; Gao Y; Wang H; Shang H; Xuan J
Int J Chron Obstruct Pulmon Dis; 2020; 15():963-971. PubMed ID: 32440108
[TBL] [Abstract][Full Text] [Related]
2. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D
Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
4. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA.
Stanford RH; Parker ED; Reinsch TK; Buikema AR; Blauer-Peterson C
Respir Med; 2019 Apr; 150():1-7. PubMed ID: 30961933
[TBL] [Abstract][Full Text] [Related]
5. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
6. Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B
Czira A; Banks V; Requena G; Wood R; Tritton T; Wild R; Compton C; Ismaila A
BMJ Open; 2024 Feb; 14(2):e072361. PubMed ID: 38326272
[TBL] [Abstract][Full Text] [Related]
7. Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.
Slade D; Ray R; Moretz C; Germain G; Laliberté F; Shen Q; Duh MS; Mahendran M; Hahn B
BMC Pulm Med; 2021 Jul; 21(1):253. PubMed ID: 34332555
[TBL] [Abstract][Full Text] [Related]
8. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
Punekar YS; Landis SH; Wurst K; Le H
Respir Res; 2015 Nov; 16():141. PubMed ID: 26572740
[TBL] [Abstract][Full Text] [Related]
9. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
Casas A; Montes de Oca M; Menezes AM; Wehrmeister FC; Lopez Varela MV; Mendoza L; Ramírez L; Miravitlles M
Int J Chron Obstruct Pulmon Dis; 2018; 13():1545-1556. PubMed ID: 29785104
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
11. Can Assessment of Disease Burden Prior to Changes in Initial COPD Maintenance Treatment Provide Insight into Remaining Unmet Needs? A Retrospective Database Study in UK Primary Care.
Landis SH; Wurst K; Le HV; Bonar K; Punekar YS
COPD; 2017 Feb; 14(1):80-85. PubMed ID: 27819513
[TBL] [Abstract][Full Text] [Related]
12. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
[TBL] [Abstract][Full Text] [Related]
13. Non-persistence and non-adherence to long-acting COPD medication therapy: A retrospective cohort study based on a large German claims dataset.
Mueller S; Wilke T; Bechtel B; Punekar YS; Mitzner K; Virchow JC
Respir Med; 2017 Jan; 122():1-11. PubMed ID: 27993284
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
Hertel N; Kotchie RW; Samyshkin Y; Radford M; Humphreys S; Jameson K
Int J Chron Obstruct Pulmon Dis; 2012; 7():183-99. PubMed ID: 22500119
[TBL] [Abstract][Full Text] [Related]
15. Concordance between reported medication taking behavior and prescription instructions for patients with chronic obstructive pulmonary disease visiting community pharmacies.
Prosser TR; Bollmeier SG
J Am Pharm Assoc (2003); 2022; 62(4):1280-1286. PubMed ID: 35277361
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns and cost of exacerbations in patients with chronic obstructive pulmonary disease using multiple inhaler triple therapy in South Korea.
Lee CH; Kim MS; Yeo SH; Rhee CK; Park HW; Yang BR; Lee J; Cho EY; Xu X; Navarro Rojas AA; Shantakumar S; Milea D; Choi NK
Respir Res; 2022 Sep; 23(1):231. PubMed ID: 36064539
[TBL] [Abstract][Full Text] [Related]
17. Intensified Therapy with Inhaled Corticosteroids and Long-Acting β
Stolz D; Hirsch HH; Schilter D; Louis R; Rakic J; Boeck L; Papakonstantinou E; Schindler C; Grize L; Tamm M
Am J Respir Crit Care Med; 2018 May; 197(9):1136-1146. PubMed ID: 29266965
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Initial LAMA versus LABA in COPD: Real-World Cohort Study.
Suissa S; Dell'Aniello S; Ernst P
COPD; 2021 Feb; 18(1):1-8. PubMed ID: 33569990
[TBL] [Abstract][Full Text] [Related]
19. Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada.
Tavakoli H; Johnson KM; FitzGerald JM; Sin DD; Gershon AS; Kendzerska T; Sadatsafavi M
Int J Chron Obstruct Pulmon Dis; 2019; 14():2003-2013. PubMed ID: 31564848
[TBL] [Abstract][Full Text] [Related]
20. Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Ann Pharmacother; 2017 Nov; 51(11):945-953. PubMed ID: 28677404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]